Falling short

ON THE 29th of November 2006, the Australian government announced plans to fund a human papillomavirus (HPV) vaccination program.

Aimed at 12-year-old girls, with a catch-up program introduced for girls and women aged 13–26 years, the chosen vaccine, Gardasil (quadrivalent human papillomavirus recombinant vaccine), is administered to participants in a three-dose schedule over a six-month period. 

Both medical and public health professions enthusiastically welcomed the funded program, and it’s easy to understand why. The vaccine